Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPPL2A | Q8TCT8 | 1/20 | 0.37 |
| ▸ | KCNA5 | P22460 | 2/20 | 0.35 |
| ▸ | MMP2 | P08253 | 3/20 | 0.35 |
| ▸ | MMP3 | P08254 | 2/20 | 0.35 |
| ▸ | MMP9 | P14780 | 2/20 | 0.35 |
| ▸ | MMP14 | P50281 | 2/20 | 0.35 |
| ▸ | MMP1 | P03956 | 1/20 | 0.35 |
| ▸ | MMP7 | P09237 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 2/20 | 0.34 |
| ▸ | CACNA1H | O95180 | 2/20 | 0.33 |
| ▸ | CA5A | P35218 | 1/20 | 0.33 |
| ▸ | AAK1 | Q2M2I8 | 4/20 | 0.33 |
| ▸ | BCL2L1 | Q07817 | 2/20 | 0.32 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.32 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.32 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.32 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.32 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.32 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5027206 | 0.90 | ACR (0.44) | SPPL2AMMP2MMP3MMP9MMP14 | |
| SCHEMBL5026552 | 0.83 | RORC (0.36) | BCL2L1MCL1KMT2A | |
| SCHEMBL7609854 | 0.77 | RORC (0.39) | BCL2L1MCL1KMT2A | |
| SCHEMBL6869361 | 0.77 | ACR (0.44) | KMT2A | |
| SCHEMBL4975791 | 0.74 | SPPL2A (0.39) | SPPL2AKCNA5MMP2MMP3MMP9 | |
| SCHEMBL4975788 | 0.73 | SPPL2A (0.69) | SPPL2A | |
| SCHEMBL7133115 | 0.73 | SPPL2A (0.46) | SPPL2ACA1CA5AAAK1HDAC3 | |
| SCHEMBL7449299 | 0.70 | CA1 (0.43) | MMP2MMP3MMP9MMP14MMP1 | |
| SCHEMBL5029148 | 0.69 | CYP3A4 (0.38) | SPPL2AMMP2MMP14MMP13 | |
| SCHEMBL6101123 | 0.69 | CYP3A4 (0.37) | KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080118969-A1 | BIS-AMINO ACID HYDROXYETHYLAMINO SULFONAMIDE RETROVIRAL PROTEASE INHIBITORS | G.D. SEARLE LLC (US) | 2008-05-22 | — | — | US | disclosed |
| US-20060189611-A1 | Amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors | G.D. SEARLE & CO. (US) | 2006-08-24 | — | — | US | disclosed |
| US-6861539-B1 | Bis-amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors | G. D. SEARLE & CO. (US) | 2005-03-01 | — | — | US | disclosed |
| US-6730669-B2 | PROPHYLACTICALLY PREVENTING RETROVIRAL INFECTION OR THE SPREAD OF A RETROVIRUS, AND TREATMENT OF A RETROVIRAL INFECTION | G. D. SEARLE & CO. | 2004-05-04 | — | — | US | disclosed |
| US-20030216435-A1 | Amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors | G. D. SEARLE & CO. | 2003-11-20 | — | — | US | disclosed |
| EP-1258491-A1 | Amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors | G.D. SEARLE & CO. (US) | 2002-11-20 | — | — | EP | disclosed |
| EP-0813542-B1 | AMINO ACID HYDROXYETHYLAMINO SULFONAMIDE RETROVIRAL PROTEASE INHIBITORS | SEARLE & CO (US) | 2002-10-16 | — | — | EP | disclosed |
| EP-1188766-A1 | Bis-amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors | G.D. Searle & Co. (US) | 2002-03-20 | — | — | EP | disclosed |
| US-6310080-B1 | TREATING RETROVIRAL INFECTIONS SUCH AS AIDS | G. D. SEARLE & CO. | 2001-10-30 | — | — | US | disclosed |
| EP-0813519-B1 | SULFONYLALKANOYLAMINO HYDROXYETHYLAMINO SULFONAMIDE RETROVIRAL PROTEASE INHIBITORS | SEARLE & CO (US) | 2001-05-09 | — | — | EP | disclosed |
| US-6169085-B1 | A VIRICIDE FOR PREVENTING AND TREATING RETROVIRAL INFECTION OR THE SPREAD OF A RETROVIRUS, INHIBITING REPLICATION OF A RETROVIRUS AND TREATING AIDS | G. D. SEARLE & COMPANY | 2001-01-02 | — | — | US | disclosed |
| US-6140505-A | REACTING A BENZO FUSED HETEROCYCLIC COMPOUND WITH AN SO3 COMPLEX IN THE PRESENCE OF A WATER IMMISCIBLE, NON-REACTIVE SOLVENT, AT A TEMPERATURE OF FROM ABOUT 0 TO ABOUT 75 DEGREES C., COOLING AND THEN ADDING OXALYL HALIDE. | G. D. SEARLE & CO. (US) | 2000-10-31 | — | — | US | disclosed |
| US-6063795-A | ENZYME INHIBITORS | G.D. SEARLE & COMPANY (US) | 2000-05-16 | — | — | US | disclosed |
| US-5972989-A | Heterocyclecarbonyl amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors | G.D. SEARLE & CO. (US) | 1999-10-26 | — | — | US | disclosed |
| US-5968970-A | TREATMENT OF HIV | G. D. SEARLE & COMPANY (US) | 1999-10-19 | — | — | US | disclosed |
| US-5965601-A | NOVEL COMPOUNDS FOR INHIBITING REPLICATION OF A RETROVIRUS; TREATING HIV | G. D. SEARLE & CO. (US) | 1999-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030216435-A1 | Amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors | DNPEP, PREP, ANPEP | SPPL2A 268/4885KCNA5 4592/4885MMP2 696/4885 |
| US-20060189611-A1 | Amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors | DNPEP, PREP, ANPEP | SPPL2A 268/4885KCNA5 4592/4885MMP2 696/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.